Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Toronto

$76,850.00

Development of SPARC mimetic peptides for targeting peritoneal metastasis of epithelial ovarian cancer

EF 2012-13

Résumé
Approximately 2500 women in Canada are diagnosed with ovarian cancer each year and about 1700 of these women die of their disease. This high mortality rate is due to a lack of early detection and to the development of chemotherapy-resistant disease. Since most women present with advanced disease, there is a desperate need for more effective therapies targeting metastatic disease. The matrix surrounding cells plays a central role in promoting or inhibiting tumor progression. Our laboratory is interested in how proteins in the extracellular matrix regulate cell behaviours. A prime focus of my laboratory is a small mobile extracellular matrix protein called SPARC. Studies have indicated that SPARC serves as a tumor suppressor and impedes metastasis of ovarian cancer. Work in my laboratory on model organisms supports a role for SPARC in stopping cell proliferation and migration. Moreover, I have found that a small part of the SPARC protein (peptide 4.2) can elicit these effects. My lab has joined with two molecular biology and one protein biochemistry laboratories working in ovarian cancer to test the ability of this small peptide to inhibit ovarian cancer progression. We will develop stable analogues of peptide 4.2 with enhanced biological function, which we will test using a variety of cell line models. We will also use a powerful mouse model of ovarian cancer to test the efficacy of promising analogues to inhibit cancer progression. This work will establish the potential of these analogues for further development as therapeutics in the treatment of advanced ovarian cancer.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
399068-2011
Name nom
Ringuette, Maurice
Department département
Cell and Systems Biology (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
76850
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
2
Nb partie
3
Application title
Development of SPARC mimetic peptides for targeting peritoneal metastasis of epithelial ovarian cancer
Keyword
NSERC
Application summary
Approximately 2500 women in Canada are diagnosed with ovarian cancer each year and about 1700 of these women die of their disease. This high mortality rate is due to a lack of early detection and to the development of chemotherapy-resistant disease. Since most women present with advanced disease, there is a desperate need for more effective therapies targeting metastatic disease. The matrix surrounding cells plays a central role in promoting or inhibiting tumor progression. Our laboratory is interested in how proteins in the extracellular matrix regulate cell behaviours. A prime focus of my laboratory is a small mobile extracellular matrix protein called SPARC. Studies have indicated that SPARC serves as a tumor suppressor and impedes metastasis of ovarian cancer. Work in my laboratory on model organisms supports a role for SPARC in stopping cell proliferation and migration. Moreover, I have found that a small part of the SPARC protein (peptide 4.2) can elicit these effects. My lab has joined with two molecular biology and one protein biochemistry laboratories working in ovarian cancer to test the ability of this small peptide to inhibit ovarian cancer progression. We will develop stable analogues of peptide 4.2 with enhanced biological function, which we will test using a variety of cell line models. We will also use a powerful mouse model of ovarian cancer to test the efficacy of promising analogues to inhibit cancer progression. This work will establish the potential of these analogues for further development as therapeutics in the treatment of advanced ovarian cancer.